31 results about "Premedication" patented technology

The present invention is a system and method that produces features and indices that indicate the presence or absence of a disease or condition, or of the progression of a disease or condition. The system and method of the present invention also produce features and indices that predict responsiveness to medication from a premedication baseline. The system and method of the present invention further incorporates a testing methodology to improve the performance characteristics of the features or indices. To obtain such features and indices, time domain, power spectrum, bispectrum and higher order spectrum values are derived from biopotential signals taken from the subject being tested.

A method for treating, ameliorating or preventing the onset of anxiety in a subject comprises administering to such subject an NMDA receptor antagonist in an amount that is sub-anesthetic and hypo-analgetic. The NMDA receptor antagonist may comprise ketamine and its pharmaceutically acceptable salts, and is administered as a premedication. Instances of use in this manner include administration prior to an anxiety causing event, such as a medical or a dental procedure. The administration of the NMDA receptor antagonist composition is particularly useful as a premedication for adults.

The invention relates to a Chinese medical composition for treating hepatitis and a preparation method thereof. The composition is prepared by traditional Chinese medicines according to the following parts by weight: 30-70 parts of fructus schisandrae, 20-50 parts of radix bupleuri, 8-20 parts of mahonia, 6-20 parts of medlar, 5-20 parts of angelica sinensis, 5-15 parts of salvia miltiorrhiza, 5-10 parts of liquorice and 5-10 parts of radix paeoniae alba. The Chinese medical composition is used for treating and preventing hepatitis for patients, and is reasonable in formula by adopting characteristic ethnomedicine formula theories and treatment principles, and safe and effective by using pure Chinese medicines for treating the hepatitis.

The invention relates to a composition for improving treating or preventing constipation comprising Cassia fermented by lactic acid bacteria as an active ingredient and a preparation method thereof. The Cassia fermented by lactic acid bacteria can used for a long time, is high in safety, and is low in side effect when be used as a crude drug. The Cassia fermented by lactic acid bacteria has an effect that more than one of the excrement amount, the moisture content and the excrement weight is increased, the effect is the same as that of a commercial Dulcolax-S with sennoside or bisacodyl and docusate sodium as the active ingredient, the commercial Dulcolax-S is an irritant constipation therapeutic agent and is forbidden to be used for health care foods due to the side effect. Thus, the Cassia fermented by lactic acid bacteria can be applied to pharmaceutical compositions for constipation treatment or prevention, or health care foods for constipation improvement or prevention. Furthermore, the Lactobacilluskefiri MJ90 bacterial strain is beneficial to the preparation of Cassia fermented by lactic acid bacteria for improving treating or preventing constipation.

Disclosed is a compound useful as an active ingredient for medicines having PDE4B inhibiting activity, in particular, therapeutic or preventive medicinal compositions for schizophrenia, Alzheimer's disease, dementia, depression and the like. Specifically, the present inventors examined compounds having PDE4B inhibiting activity and found that a tricyclic or tetracyclic imidazo[1,2-a]pyridine derivative or salts thereof had superior PDE4B inhibiting activity. This imidazo[1,2-a]pyridine derivative can be used in therapeutic and preventative agents for schizophrenia, Alzheimer's disease, dementia, depression, and the like.

The invention relates to an application of a daphniphyllum calycinum benth and red-knees herb composition in preparing a medicament for preventing and treating rheumatic diseases. The invention is characterized in that during preparing the medicament for preventing and treating the rheumatic diseases, an adopted effective constituent is prepared from the following traditional Chinese medicine raw materials in parts by weight: 1-9 parts of daphniphyllum calycinum benth and 1-9 parts of red-knees herb. The medicament prepared by the application has definite curative effect for preventing and treating the rheumatic diseases, durable action and no obvious side effect and better solves the problems of treatment drugs and prevention drugs for the rheumatic diseases.

The present invention identifies a cancer antigen protein which is expressed specifically on the surface of a cancer cell, and provides a use of an antibody, which targets the cancer antigen protein, as a therapeutic and/or prophylactic agent for cancer. Specifically disclosed is a pharmaceutical composition for the treatment and/or prevention of cancer, which is characterized by containing, as an active ingredient, an antibody that is immunologically reactive with a partial polypeptide of CAPRIN-1 represented by the even-numbered sequences of SEQ ID NOS: 2-30, said partial polypeptide comprising the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity to the amino acid sequence, or a fragment of the antibody.

The present invention provides an effective method for inhibiting antro-duodenal motility in healthy subjects and patients suffering from various disorders, without the side effects associated with other pharmaceutical compositions. GLP-1 slows antro-duodenal motility and may be used for the treatment or prevention of gastrointestinal disorders such as diarrhea, postoperative dumping syndrome and irritable bowel syndrome, and also premedication in endoscopic procedures.

The present invention relates to a novel nasal spray containing an aqueous solution or a fluid with an anxiolytic or anticonvulsant substance, wherein the nasal spray is characterized in that with the nasal spray, two sprays with each an equivalent, defined volume of the aqueous solution or liquid of the active agent, can be intranasally administered to a patient and wherein the nasal spray allows for an administration, independent of the spatial orientation of the nasal spray in any position of the patient (standing upright, sitting, lying or in any intermediate position). The nasal spray can be used directly without prior activation. Preferably it is apparent from the nasal spray whether a spray or even a second spray has been made with the nasal spray. Preferably, a spray of the nasal spray can be administered one-handed by the patient or a third person. The active agent in the inventive nasal spray is a benzodiazepine or a GABA-receptor agonist, preferably midazolam or a derivative thereof or a salt of these active agents. The nasal spray according to the present invention may be used for sedation, premedication or treatment of patients with claustrophobia, anxiety disorders or panic attacks or for the treatment of convulsions in CNS diseases, particularly in epileptic seizures or other manifestations of seizures (e.g. febrile convulsions). The invention also relates to a method for hermetically sealing an active agent container for use in supplying an nasal spray in accordance with the invention. The invention also relates to a method of detection by localizing the locally precise administration of an active agent in nasal application, as well as a nasal spray, preferably a bi-dose nasal spray, for which, using the cited method of detection, it has been shown both visually (qualitatively) and quantitatively that an orientation-independent, uniform and locally precise administration of the dose of the active agent onto the nasal mucosa of a patient can be achieved. Also provided is a method for airless and air-tight sealing of an active agent container in accordance with the invention.

The invention discloses the application of CD93 in the preparation of an early warning infantile hemangioma (IH) umbilical blood assay kit and a therapeutic drug. A study found that the neonatal umbilical blood serum CD93 has an important role in predicting/warning IH, and is a serum marker of IH tumors. Because IH is the most common benign tumor in infants, and the neonatal umbilical blood is easy to sufficiently collect in the early stage of IH, has no trauma, and is easy to be accepted by family members, the development of using CD93 as a umbilical blood assay kit or test paper for predicting/warning protein for warning the occurrence of IH has extremely important clinical significance and social values on the early monitoring, the early detection and the early treatment of IH, minimizing the teratogenesis rate of severe IH, and reducing the rate of misdiagnosis and mistreatment. In addition, the CD93, as transmembrane protein, can promote angiogenesis of hemangioblast stem cells, has important significance in anti-angiogenesis therapeutic targets, and can be used for preparing related therapeutic drugs and preventive drugs for early treatment and prevention of IH.

The invention discloses a preventive medicine applied before an elective orthopedic surgery. According to the prescription, the medicine consists of 10-30 parts of arenicola cristata, 15-25 parts of cladosiphon okamuranus, 5-15 parts of lentinus lepideus fr, 5-15 parts of longleaf bastardtoadflax herb, 6-10 parts of laportea violacea gaghep, 3-10 parts of pineapple peels, 6-12 parts of moellendorf's spidemoss herb, 3-10 parts of pyropolyporus formentarius teng, 6-12 parts of herb of elsholtzia rugulosa hemsl, 2-5 parts of swamp currant, 1-3 parts of codariocalyx motorius and 1-3 parts of eurya hebeclados. The medicine disclosed by the invention is reasonable in prescription and concrete in curative effect, and the medicine can be used for effectively preventing un-healed wounds in patients with diabetics in the orthopedic surgery.

The present invention discloses an antibody that targets a cancer antigen protein expressed specifically on the surface of cancer cells, and the application of the antibody in a treatment and/or preventative agent for said cancer. Specifically disclosed are: an antibody or a fragment thereof, said antibody being immunologically reactive with a partial polypeptide of CAPRIN-1 comprising the amino acid sequence represented by SEQ ID NO: 5 or an amino acid sequence having 80% or more sequence identity to the amino acid sequence represented by SEQ ID NO: 5; and a pharmaceutical composition for the treatment and/or prevention of cancer, said pharmaceutical composition being characterized by containing, as an active ingredient, the antibody or a fragment thereof.

The invention discloses a method for targeted application of ultrasound fiberoptic bronchoscopic tumor body, which comprises the following steps: firstly, local anesthesia with medication before operation, and the airway is explored according to a conventional fiberoptic bronchoscopy method to understand the location and growth of the lesion; Conventional fiberoptic bronchoscopic high-frequency electric snare and nitrogen sub-knife equipment are used to resect the tumor in the trachea; the conventional fiberoptic bronchoscope is withdrawn, and the ultrasonic bronchoscope is sent into the airway, and the ultrasonic probe detects the depth of tumor invasion into the trachea and the root and The relationship between the surrounding tissues; under the guidance of the ultrasound bronchoscope, the chemotherapy drugs cisplatin and cetuximab were injected at multiple points in the submucosal part of the tumor tissue; the ultrasound bronchoscope was withdrawn, and the conventional bronchoscope was sent into the airway again, And multi-point freezing treatment was given to the tumor site; after freezing treatment, dexamethasone and gentamicin were sprayed locally at the opening of the main bronchus on the side of the tumor lesion.